Question · Q3 2025
Felipe, on behalf of Richard Neueter, asked about the customer acquisition cost for Type 2 patients compared to Type 1, and how Insulet's scale provides an advantage in converting this patient population, given the early adoption stages.
Answer
Ashley McEvoy, President and CEO, noted that Insulet closely monitors customer acquisition costs. Eric Benjamin, COO, explained that leveraging the common call point with Type 1 prescribers creates strong commercial synergy and efficiency for Type 2. While activating new prescribers initially incurs higher costs, Insulet is selective and efficient, focusing on high-opportunity areas and closely managing overall customer acquisition costs.
Ask follow-up questions
Fintool can predict
PODD's earnings beat/miss a week before the call